Sichuan Huiyu Pharmaceutical Co Ltd

Huiyu Pharmaceutical announced on September 30 that its subsidiary Seacross Europe Pharma Limited has recently obtained marketing authorization from the French National Agency for the Safety of Medicines and Health Products for paclitaxel for injection, albumin-bound. The product is indicated for the treatment of adult patients with metastatic breast cancer, metastatic pancreatic adenocarcinoma, and adult patients with non-small cell lung cancer who are not candidates for surgery or radiotherapy. In the first half of 2026, Huiyu Pharmaceutical achieved revenue of 552 million yuan and net profit attributable to the parent company of 57.65 million yuan.

The National Medical Products Administration will advance the implementation of the pharmaceutical trial data protection system, establish market exclusivity periods for pediatric drugs and rare disease medications, and strengthen pre-guidance for innovative drugs with new targets and mechanisms. A responsible official from the NMPA stated that it will also expand the "Spring Rain Action" for transforming clinical innovations in medical devices, and formulate clinical trial and review guiding principles in frontier areas such as brain-computer interfaces. Zhongtai Securities noted that AI4S is expanding from single-point tool applications to coordinated development across data, models, wet-lab experiments, and R&D processes, and that life science upstream and CXO companies with high-quality data accumulation, automated experimental platforms, and industrial customer bases are expected to benefit continuously. As of 11:22 on September 21, 2026, the Penghua STAR Market Healthcare ETF rose 3.87%, with constituent stock HitGen up 14.54%, and Zelgen Biopharmaceuticals and Huiyu Pharmaceutical following the gains; the Penghua Hang Seng Biotech ETF rose 4.56%.

Huiyu Pharmaceutical announced that its wholly-owned subsidiary Huiyu Haiyue has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial for HY07121 for injection, administered subcutaneously, for the treatment of advanced solid tumors has been approved. The drug is an anti-PD-1, anti-TIGIT, IL-15/IL-15Rα triple-target antibody fusion protein, classified as a Class 1 innovative therapeutic biological product, aimed at improving patient convenience and reducing side effects. As of the announcement date, no similar product has been marketed.

Huiyu Pharmaceutical recently received government grants totaling 5 million yuan. The grants are income-related and account for 20.03% of the company's audited net profit for the most recent fiscal year. The company will classify these grants as income-related government grants in accordance with the Accounting Standards for Business Enterprises.